Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Detalhes bibliográficos
Autor(a) principal: LeFevre, Inge
Data de Publicação: 2023
Outros Autores: Bravo, Lulu, Folschweiller, Nicolas, Medina, Eduardo Lopez, Moreira Jr, Edson Duarte, Nordio, Francesco, Sharma, Mayuri, Tharenos, Leslie M., Tricou, Vianney, Watanaveeradej, Veerachai, Winkle, Peter J., Biswal, Shibadas
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/58942
Resumo: Takeda Pharmaceuticals..
id CRUZ_d8a954fa886a6cae8b9f29fc94fc9d69
oai_identifier_str oai:www.arca.fiocruz.br:icict/58942
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling LeFevre, IngeBravo, LuluFolschweiller, NicolasMedina, Eduardo LopezMoreira Jr, Edson DuarteNordio, FrancescoSharma, MayuriTharenos, Leslie M.Tricou, VianneyWatanaveeradej, VeerachaiWinkle, Peter J.Biswal, Shibadas2023-06-06T13:46:14Z2023-06-06T13:46:14Z2023LEFEVRE, Inge et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. npj Vaccines, v. 75, p. 1-9, 2023.2059-0105https://www.arca.fiocruz.br/handle/icict/5894210.1038/s41541-023-00670-6Takeda Pharmaceuticals..Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.University of the Philippines. College of Medicine. Manila, Philippines.Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.Universidad Del Valle. Centro de Estudios en Infectología Pediatrica CEIP. Department of Pediatrics. Clínica Imbanaco. Grupo Quironsalud. Cali, Colombia.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Associação Obras Sociais Irmã Dulce Hospital Santo Antônio. Salvador, BA, Brasil.Takeda Vaccines Inc. Cambridge, MA, USA.Takeda Vaccines Inc. Cambridge, MA, USA.The Division of Environmental and Occupational Health Sciences. University of Illinois at Chicago School of Public Health. Chicago, IL, USA.Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.Department of Pediatrics. Phramongkutklao Hospital and Faculty of Medicine. Kasetsart University. Bangkok, Thailand.Anaheim Clinical Trials. Anaheim, CA, USA.Takeda Vaccines Inc. Cambridge, MA, USA.Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic to many tropical and subtropical regions, is traditionally thought of as a pediatric disease but is now a global threat to both children and adults. We bridged immunogenicity data from a phase 3 efficacy study of a tetravalent dengue vaccine (TAK-003), performed in children and adolescents living in endemic areas, with an immunogenicity study in adults in non-endemic areas. Neutralizing antibody responses were comparable in both studies following receipt of a two-dose TAK-003 schedule (months 0 and 3). Similar immune responses were observed across exploratory assessments of additional humoral responses. These data support the potential for clinical efficacy of TAK-003 in adults.engNature ResearchImunogenicidadeVacina tetravalenteDengue (TAK-003)CriançasAdolescentesAdultosImmunogenicityTetravalent vaccineDengue (TAK-003)ChildrenAdolescentsAdultsImunogenicidade da vacinaVacinas combinadasDengueCriançaAdolescenteAdultoBridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adultsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/58942/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALLeFevre, I. Bridging the immunogenicity....pdfLeFevre, I. Bridging the immunogenicity....pdfapplication/pdf636624https://www.arca.fiocruz.br/bitstream/icict/58942/2/LeFevre%2c%20I.%20Bridging%20the%20immunogenicity....pdf5dcce2e864cf16cea5afa35e28093c4cMD52icict/589422023-06-06 10:46:15.229oai:www.arca.fiocruz.br:icict/58942Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-06-06T13:46:15Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
title Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
spellingShingle Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
LeFevre, Inge
Imunogenicidade
Vacina tetravalente
Dengue (TAK-003)
Crianças
Adolescentes
Adultos
Immunogenicity
Tetravalent vaccine
Dengue (TAK-003)
Children
Adolescents
Adults
Imunogenicidade da vacina
Vacinas combinadas
Dengue
Criança
Adolescente
Adulto
title_short Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
title_full Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
title_fullStr Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
title_full_unstemmed Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
title_sort Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
author LeFevre, Inge
author_facet LeFevre, Inge
Bravo, Lulu
Folschweiller, Nicolas
Medina, Eduardo Lopez
Moreira Jr, Edson Duarte
Nordio, Francesco
Sharma, Mayuri
Tharenos, Leslie M.
Tricou, Vianney
Watanaveeradej, Veerachai
Winkle, Peter J.
Biswal, Shibadas
author_role author
author2 Bravo, Lulu
Folschweiller, Nicolas
Medina, Eduardo Lopez
Moreira Jr, Edson Duarte
Nordio, Francesco
Sharma, Mayuri
Tharenos, Leslie M.
Tricou, Vianney
Watanaveeradej, Veerachai
Winkle, Peter J.
Biswal, Shibadas
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv LeFevre, Inge
Bravo, Lulu
Folschweiller, Nicolas
Medina, Eduardo Lopez
Moreira Jr, Edson Duarte
Nordio, Francesco
Sharma, Mayuri
Tharenos, Leslie M.
Tricou, Vianney
Watanaveeradej, Veerachai
Winkle, Peter J.
Biswal, Shibadas
dc.subject.other.en_US.fl_str_mv Imunogenicidade
Vacina tetravalente
Dengue (TAK-003)
Crianças
Adolescentes
Adultos
topic Imunogenicidade
Vacina tetravalente
Dengue (TAK-003)
Crianças
Adolescentes
Adultos
Immunogenicity
Tetravalent vaccine
Dengue (TAK-003)
Children
Adolescents
Adults
Imunogenicidade da vacina
Vacinas combinadas
Dengue
Criança
Adolescente
Adulto
dc.subject.en.en_US.fl_str_mv Immunogenicity
Tetravalent vaccine
Dengue (TAK-003)
Children
Adolescents
Adults
dc.subject.decs.en_US.fl_str_mv Imunogenicidade da vacina
Vacinas combinadas
Dengue
Criança
Adolescente
Adulto
description Takeda Pharmaceuticals..
publishDate 2023
dc.date.accessioned.fl_str_mv 2023-06-06T13:46:14Z
dc.date.available.fl_str_mv 2023-06-06T13:46:14Z
dc.date.issued.fl_str_mv 2023
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv LEFEVRE, Inge et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. npj Vaccines, v. 75, p. 1-9, 2023.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/58942
dc.identifier.issn.en_US.fl_str_mv 2059-0105
dc.identifier.doi.none.fl_str_mv 10.1038/s41541-023-00670-6
identifier_str_mv LEFEVRE, Inge et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. npj Vaccines, v. 75, p. 1-9, 2023.
2059-0105
10.1038/s41541-023-00670-6
url https://www.arca.fiocruz.br/handle/icict/58942
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/58942/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/58942/2/LeFevre%2c%20I.%20Bridging%20the%20immunogenicity....pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
5dcce2e864cf16cea5afa35e28093c4c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324665316278272

Registros relacionados